Study Comparing Enbrel (Etanercept) Plus Methotrexate Versus Enbrel Alone in Active Rheumatoid Arthritis Despite Current Methotrexate Therapy
Information source: Wyeth is now a wholly owned subsidiary of Pfizer
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Rheumatoid Arthritis
Intervention: Methotrexate plus ENBREL or ENBREL alone (Drug)
Phase: Phase 4
Sponsored by: Wyeth is now a wholly owned subsidiary of Pfizer
Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
To investigate the changes in MRI-derived markers of joint inflammation and destruction and
in biochemical markers of connective tissue metabolism and angiogenesis in rheumatoid
arthritis patients treated with Enbrel and Enbrel+methotrexate.
Official title: A Randomized Comparison of the Safety and Efficacy of Enbrel (Etanercept) Plus Methotrexate Versus Enbrel Alone in Patients With Active Rheumatoid Arthritis Despite Current Methotrexate Therapy
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Primary outcome: To assess the efficacy and safety of substituting ENBREL versus adding ENBREL to Methotrexate in patients with active Rheumatoid Arthritis despite adequate Methotrexate therapy.
Secondary outcome: To evaluate the effect of combination therapy with ENBREL plus Methotrexate versus ENBREL alone on health-related quality of life measures.
Minimum age: 18 Years.
Maximum age: N/A.
- In the case of contra-indications for MRI, the patient may participate in the
remaining part of the project.
Locations and Contacts
Starting date: March 2003
Last updated: February 20, 2013